Last reviewed · How we verify

Squamous cell carcinoma — Treatment Landscape & Competitive Intelligence

Squamous cell carcinoma (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Squamous cell carcinoma, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Libtayo CEMIPLIMAB Regeneron Pharmaceuticals PD-1 2018-01-01
Blenoxane BLEOMYCIN Bristol-Myers Squibb Cytoprotective Agent Aspartyl/asparaginyl beta-hydroxylase 1973-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 1 drug in Squamous cell carcinoma
  2. Bristol-Myers Squibb · 1 drug in Squamous cell carcinoma
  3. Regeneron Pharmaceuticals · 1 drug in Squamous cell carcinoma

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Squamous cell carcinoma:

Cite this brief

Drug Landscape (2026). Squamous cell carcinoma — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/squamous-cell-carcinoma. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing